吉西他滨致血小板增多症的抗栓治疗策略：病例报告及文献复习

严颐丹; 苏颖杰; 罗晓枫; 蓝颖

doi:10.13748/j.cnki.issn1007-7693.20252270

吉西他滨致血小板增多症的抗栓治疗策略：病例报告及文献复习

Treatment Strategy for Gemcitabine-Induced Thrombocytosis: Case Reports and Literature Review

摘要

摘要:
目的探讨吉西他滨与血小板增多症的临床相关性及其抗栓治疗策略。
方法报道2例肿瘤患者接受常规剂量吉西他滨化疗后出现血小板增多症的临床过程，并结合文献复习，分析其临床特征、基础疾病及药物治疗情况。
结果 2例患者出现的血小板增多症很可能与使用吉西他滨相关，对静脉血栓栓塞高风险患者进行预防性抗凝，2例患者均未发生血栓事件。
结论吉西他滨相关血小板增多症的发生率不低，但其发生机制尚不明确。针对此类患者，临床药师应结合血小板计数及静脉血栓栓塞风险进行评估，提供个体化用药建议，以保障临床用药安全有效。

Abstract:
OBJECTIVE To investigate the clinical correlation between gemcitabine and thrombocytosis and its antithrombotic management strategies.
METHODS Two cases of thrombocytosis occurring in cancer patients after conventional-dose gemcitabine chemotherapy were reported. Their clinical features, underlying diseases, and drug treatment courses were analyzed in combination with a literature review.
RESULTS Thrombocytosis in the two patients was likely associated with the use of gemcitabine. Prophylactic anticoagulation was administered to patients at high risk of venous thromboembolism, and no thrombotic events occurred in either case.
CONCLUSION The incidence of gemcitabine-related thrombocytosis is not low, and its mechanism remains unclear. For such patients, clinical pharmacists should provide management recommendations based on platelet levels and venous thromboembolism risk to ensure medication safety and efficacy.

HTML全文

参考文献(24)

施引文献

资源附件(0)